Markets

 

LexaGene’s MiQLab™ system is designed to respond to multi-billion dollar markets in need of rapid automated pathogen detection and customized testing.

 

Human Clinical Diagnostics

> Learn more

Veterinary Diagnostics

  • Companion animal diagnostics
  • Infections and antibiotic resistance can be quickly detected so the appropriate antibiotic is prescribed
  • Reference laboratory accounts for largest market share of the veterinary diagnostics market
  • North America accounts for largest segment due to well-established animal healthcare market
  • $2.2 billion USD Market by 2024

> Learn more

Food Safety Testing

  • 1.1 B tests performed per year
  • Mandatory food testing now required
  • Prevents costly recalls, brand damage
  • Fresher, safer product to customer (eliminates 2-day hold on food)
  • Hundreds of food recalls in the US each year
  • Major disease-causing pathogen: Salmonella/E. coli
  • $23.4 Billion USD market by 2024

> Learn more

Open-Access Markets

$20 Billion USD markets:

  • Labs looking for automation and customization
  • Pharma, biotech, academic labs – (18,000 moderate complexity CLIA labs in the US)
  • PCR market – $4.33B USD by 2026
  • Genotyping – $11.8B USD

Other open-access markets:

> Learn more

Pandemic Prevention

Threat of next outbreak or pandemic is real

  • LexaGene technology ideally suited to contain outbreaks
  • Need rapid time to results for quarantine decisions
  • Test at point-of-need required (hospitals, clinics, institutions)
  • Need tests that can be easily deployed
  • Require reagents that are easy to manufacture for worldwide coverage
  • Current testing methods don’t meet the needs

More Markets

LexaGene’s technology has a wide range of applications across other markets at point-of-need:

  • Cruise ships
  • Biodefense
  • Military bases and aircraft carriers
  • Etc.